Albireo Launches Expanded Access Program for Odevixibat for Patients in the U.S., Canada, Australia and Europe
Excerpt from the Press Release:
“BOSTON, July 20, 2020 (GLOBE NEWSWIRE) — Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the launch of an Expanded Access Program (EAP) for investigational lead product candidate odevixibat, a highly potent and selective inhibitor of the ileal bile acid transporter (IBAT), for patients with progressive familial intrahepatic cholestasis (PFIC) in the U.S., Canada, Australia and Europe.”
“A tremendous need remains for a pharmacologic treatment option for PFIC, a life-threatening, ultra-rare, pediatric liver disease with serious and debilitating symptoms. Through our open-label PEDFIC 2 trial, and now our Expanded Access Program (EAP), we hope to increase access to odevixibat for all eligible patients to the greatest extent possible until odevixibat is commercially available,”Ron Cooper, President and Chief Executive Officer of Albireo.
Click the button below to read the Press Release:
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?